Precipio, Inc. (NASDAQ:PRPO) Short Interest Update

Precipio, Inc. (NASDAQ:PRPO) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 4,048 shares, a growth of 22.5% from the January 15th total of 3,304 shares. Based on an average daily trading volume, of 10,844 shares, the short-interest ratio is presently 0.4 days. Approximately 0.3% of the shares of the stock are sold short. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 10,844 shares, the short-interest ratio is presently 0.4 days.

Precipio Trading Up 4.3%

Shares of NASDAQ PRPO opened at $23.39 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06. Precipio has a 12 month low of $3.90 and a 12 month high of $28.50. The company has a market cap of $40.93 million, a price-to-earnings ratio of -28.52 and a beta of 1.20. The business has a fifty day simple moving average of $23.57 and a 200-day simple moving average of $20.57.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.The company had revenue of $6.77 million for the quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on PRPO. Wall Street Zen upgraded shares of Precipio to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Precipio presently has an average rating of “Sell”.

Hedge Funds Weigh In On Precipio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new stake in shares of Precipio during the 3rd quarter valued at $194,000. Renaissance Technologies LLC raised its holdings in shares of Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares in the last quarter. Evernest Financial Advisors LLC acquired a new stake in Precipio during the third quarter valued at $374,000. Geode Capital Management LLC grew its stake in Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 789 shares in the last quarter. Finally, Topline Capital Management LLC acquired a new position in Precipio in the 3rd quarter worth about $1,158,000. Institutional investors and hedge funds own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.